The anti-tumor necrosis factor (anti-TNF) agents such as infliximab, etanercept and adalimumab, used as an alternative or in combination with synthetic disease-modifying antirheumatic drugs (DMARDs) in the treatment of juvenile idiopathic arthritis (JIA) and JIA-associated uveitis. This evidence concerns the gene TNF and juvenile idiopathic arthritis.